See more : Precision Camshafts Limited (PRECAM.BO) Income Statement Analysis – Financial Results
Complete financial analysis of MiMedx Group, Inc. (MDXG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MiMedx Group, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Crane Company (CR) Income Statement Analysis – Financial Results
- Pfizer Limited (PFIZER.BO) Income Statement Analysis – Financial Results
- CarePayment Technologies, Inc. (CPYT) Income Statement Analysis – Financial Results
- Blackstone Resources AG (BLS.SW) Income Statement Analysis – Financial Results
- PT TIMAH Tbk (PTTMF) Income Statement Analysis – Financial Results
MiMedx Group, Inc. (MDXG)
About MiMedx Group, Inc.
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 321.48M | 267.84M | 258.62M | 248.23M | 299.26M | 359.11M | 321.14M | 245.02M | 187.30M | 118.22M | 59.18M | 27.05M | 7.76M | 788.87K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 54.63M | 48.32M | 43.28M | 39.33M | 43.08M | 36.39M | 35.22M | 32.41M | 20.20M | 12.67M | 9.33M | 5.19M | 3.15M | 1.72M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 266.84M | 219.53M | 215.33M | 208.90M | 256.17M | 322.73M | 285.92M | 212.61M | 167.09M | 105.56M | 49.85M | 21.87M | 4.61M | -931.19K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 83.01% | 81.96% | 83.26% | 84.16% | 85.60% | 89.87% | 89.03% | 86.77% | 89.21% | 89.29% | 84.24% | 80.82% | 59.35% | -118.04% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 12.67M | 22.83M | 17.34M | 11.72M | 11.14M | 15.77M | 17.90M | 12.04M | 8.41M | 7.05M | 4.84M | 2.88M | 2.60M | 2.75M | 4.02M | 2.01M | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.96M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 211.12M | 208.79M | 198.36M | 181.02M | 198.21M | 258.53M | 220.12M | 180.00M | 133.38M | 90.48M | 46.23M | 20.97M | 11.76M | 6.85M | 7.96M | 8.66M | 36.81K | 16.15K |
| Other Expenses | 5.94M | 12.88M | 4.61M | 60.54M | 67.54M | 527.00K | -87.00K | 2.13M | 933.00K | 928.00K | 1.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 229.73M | 244.50M | 220.31M | 253.28M | 276.89M | 326.65M | 239.70M | 194.16M | 142.73M | 98.46M | 52.12M | 23.86M | 14.37M | 9.60M | 11.98M | 10.67M | 36.81K | 16.15K |
| Cost & Expenses | 284.36M | 292.81M | 263.60M | 292.61M | 319.97M | 363.04M | 274.92M | 226.57M | 162.93M | 111.12M | 61.45M | 29.04M | 17.52M | 11.32M | 11.98M | 10.67M | 36.81K | 16.15K |
| Interest Income | 0.00 | 5.02M | 4.98M | 7.94M | 4.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 59.55K | 519.71K | 0.00 | 0.00 |
| Interest Expense | 6.46M | 5.02M | 4.98M | 7.94M | 4.71M | 0.00 | 0.00 | 339.00K | 86.00K | 48.00K | 1.37M | 2.31M | 432.97K | 599.65K | 0.00 | 0.00 | 2.05K | 590.00 |
| Depreciation & Amortization | 3.43M | 4.05M | 6.17M | 7.84M | 8.53M | 6.92M | 5.77M | 5.46M | 2.73M | 2.13M | 1.69M | 1.85M | 1.78M | 1.11M | 1.09M | 500.26K | 0.00 | 0.00 |
| EBITDA | 40.52M | -10.69M | -1.89M | -45.76M | -12.35M | 2.99M | 53.04M | 23.91M | 27.10M | 9.23M | -947.35K | -3.51M | -7.98M | -9.71M | -10.89M | -10.83M | -36.81K | -16.15K |
| EBITDA Ratio | 12.60% | -7.81% | 0.07% | -15.11% | -4.24% | 0.83% | 16.51% | 9.76% | 14.47% | 7.80% | -0.98% | -7.36% | -102.81% | -1,230.60% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 37.12M | -24.97M | -5.01M | -44.37M | -20.71M | -3.92M | 46.22M | 18.45M | 24.36M | 7.10M | -2.64M | -5.36M | -9.76M | -10.53M | -11.98M | -17.85M | -36.81K | -16.15K |
| Operating Income Ratio | 11.55% | -9.32% | -1.94% | -17.87% | -6.92% | -1.09% | 14.39% | 7.53% | 13.01% | 6.01% | -4.46% | -19.80% | -125.78% | -1,335.15% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6.48M | -5.02M | -2.99M | -16.15M | -4.43M | 527.00K | -1.14M | -339.00K | -86.00K | -48.00K | -1.37M | -2.31M | -432.97K | -887.10K | 59.55K | -5.39M | -2.05K | -634.63K |
| Income Before Tax | 30.63M | -29.99M | -10.04M | -61.54M | -25.59M | -3.40M | 45.09M | 18.11M | 24.28M | 7.05M | -4.01M | -7.66M | -10.19M | -11.42M | -11.92M | -17.37M | -38.86K | -16.74K |
| Income Before Tax Ratio | 9.53% | -11.20% | -3.88% | -24.79% | -8.55% | -0.95% | 14.04% | 7.39% | 12.96% | 5.96% | -6.78% | -28.32% | -131.36% | -1,447.60% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -36.81M | 206.00K | 247.00K | -12.26M | -5.00K | 26.58M | -19.64M | 6.13M | -5.17M | 832.00K | 99.61K | 2.31M | 432.97K | 887.10K | -59.55K | -477.93K | 0.00 | 0.00 |
| Net Income | 67.44M | -30.20M | -10.29M | -49.28M | -25.58M | -29.98M | 64.73M | 11.97M | 29.45M | 6.22M | -4.11M | -7.66M | -10.19M | -11.42M | -11.92M | -17.37M | -38.86K | -16.74K |
| Net Income Ratio | 20.98% | -11.27% | -3.98% | -19.85% | -8.55% | -8.35% | 20.16% | 4.89% | 15.72% | 5.26% | -6.95% | -28.32% | -131.36% | -1,447.60% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.48 | -0.27 | -0.09 | -0.46 | -0.24 | -0.28 | 0.61 | 0.00 | 0.28 | 0.06 | -0.04 | -0.09 | -0.14 | -0.19 | -0.32 | -3.00 | -0.01 | 0.00 |
| EPS Diluted | 0.38 | -0.27 | -0.09 | -0.46 | -0.24 | -0.28 | 0.56 | 0.00 | 0.26 | 0.05 | -0.04 | -0.09 | -0.14 | -0.19 | -0.32 | -3.00 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 116.50M | 112.91M | 110.35M | 108.26M | 106.95M | 105.60M | 106.12M | 105.93M | 105.93M | 105.79M | 96.29M | 81.65M | 72.45M | 59.14M | 37.74M | 5.79M | 7.40M | 5.68M |
| Weighted Avg Shares Out (Dil) | 145.96M | 112.91M | 110.35M | 108.26M | 106.95M | 105.60M | 116.11M | 112.65M | 113.63M | 113.30M | 96.29M | 81.65M | 72.45M | 59.14M | 37.74M | 5.79M | 7.40M | 5.68M |
Why Shares of MiMedx Are Collapsing Today
Why MiMedx Shares Are Diving Today
Mimedx Stock Plunges After Disappointing Data From Musculoskeletal Trials
MIMEDX Reports Top-line Data from Two Late-Stage Musculoskeletal Trials with Proprietary Amniotic Tissue Technology
MIMEDX Announces Effectiveness of Shelf Registration Statement
MIMEDX to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
MIMEDX Announces Filing of Shelf Registration Statement with Securities and Exchange Commission
Medicare Data: Significant Reductions in Amputations, Emergency Visits, and Hospital Readmissions Associated with Advanced Treatment Using Skin Substitute Products for Lower Extremity Diabetic Ulcers (LEDUs)
MIMEDX Promotes Marion Snyder to Chief of Staff, Senior Vice President, Government Affairs
MiMedx Group, Inc. (MDXG) CEO Tim Wright on Q2 2021 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports